health
Cervomed Announces Pharmacokinetic Results With New Neflamapimod Oral Tablet Formulation And Secures FDA Removal Of Drug Exposure Limit
(MENAFN - GlobeNewsWire - Nasdaq) New 50 mg tablet formulation delivers an improved pharmacokinetic profile and enables greater exposure and patient convenience FDA removal of the prior drug ...
ONLY AVAILABLE IN PAID PLANS
Read Full ArticleShare this story
Up next
Related Stories
Meet Jordic: The Unlikely Voice Of A Heart-Health Warning Men Need To Hear
Menafn
YR Fitness Plans To Expand One-Stop Gym Solutions With Design And Fit-Out Services
Menafn
Dr. Simon Ourian, Whose Patients Have Included Kim Kardashian And Adriana Lima, Launches 'Ask Dr. Ourian'
Menafn
Regentis Biomaterials And The Shift From Symptom Management To Structural Repair In Knee Cartilage Care
Menafn
Stucco Restoration At Hillsborough Nursing Center Brings A Beneficial Side Effect
Menafn